Access Equity Research

News

Virtual & In-person Roadshows / Conferences

Channelchek Premium. Access more at no cost. 

The site "channelcheck" is opened on the phone

Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost. 

Access to Exclusive Content. FREE for Registered Users Only. 

Click “Log In” to agree to Channelchek.com <a href="#">Terms of Use</a> and acknowledge that Channelchek.com <a href="#">Privacy Policy</a> applies to you.

Welcome to the Channelchek Investor Community

Informed investors make more money. And it’s all about timing. Get it when it happens.

Inbox Intel from Channelchek.

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Wednesday, April 30, 2025



Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Solid Q1 results. The company reported Q1 revenue growth of 13.4% year over year to $16.0 million, roughly in line with our estimate of $16.2 million. Adj. EBITDA of $0.9 million was better than our estimate of $0.4 million.



B2C momentum. The strong quarterly revenue growth was driven by the company’s B2C segment. Importantly, the company is in the midst of optimizing pricing for its popular beauty app subscription and recently introduced a higher margin premium subscription plan. We believe the B2C segment is poised for continued revenue growth throughout 2025.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/27434">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Wednesday, April 30, 2025



Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Solid Q1 results. The company reported Q1 revenue growth of 13.4% year over year to $16.0 million, roughly in line with our estimate of $16.2 million. Adj. EBITDA of $0.9 million was better than our estimate of $0.4 million.



B2C momentum. The strong quarterly revenue growth was driven by the company’s B2C segment. Importantly, the company is in the midst of optimizing pricing for its popular beauty app subscription and recently introduced a higher margin premium subscription plan. We believe the B2C segment is poised for continued revenue growth throughout 2025.



Get the Full Report







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Perfect . (PERF) - Q1 Revenue Growth Demonstrates Resilience

PERF

Perfect

Software Application

Technology

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Wednesday, April 30, 2025



Travelzoo® provides its 30 million members with exclusive offers and one-of-a-kind experiences personally reviewed by our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. We work in partnership with more than 5,000 top travel suppliers—our long-standing relationships give Travelzoo members access to irresistible deals.



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Reports solid Q1 results.&nbsp;Q1 revenues accelerated, up 5.3%, from the 2.2% decline in the fourth quarter, reflecting the early adoption of the company's transformative migration toward a subscription model. Results were in line with expectations, with adj. EBITDA of $4.4 million and positive free cash flow generation of $3.3 million.&nbsp;



Revenues expected to accelerate.&nbsp;Management indicated that second quarter revenue growth is expected to accelerate, double the rate of the first quarter's 5.3%. The enhanced revenue growth reflects the success of converting legacy subscribers to a paid subscription. The paid subscription began in the first quarter of 2025, with subscription revenues recognized pro-ratably over the subscription period. As such, we expect that revenue growth will accelerate as it adds subscriptions throughout the year.&nbsp;



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/27438">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Wednesday, April 30, 2025



Travelzoo® provides its 30 million members with exclusive offers and one-of-a-kind experiences personally reviewed by our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. We work in partnership with more than 5,000 top travel suppliers—our long-standing relationships give Travelzoo members access to irresistible deals.



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Reports solid Q1 results.&nbsp;Q1 revenues accelerated, up 5.3%, from the 2.2% decline in the fourth quarter, reflecting the early adoption of the company&#8217;s transformative migration toward a subscription model. Results were in line with expectations, with adj. EBITDA of $4.4 million and positive free cash flow generation of $3.3 million.&nbsp;



Revenues expected to accelerate.&nbsp;Management indicated that second quarter revenue growth is expected to accelerate, double the rate of the first quarter&#8217;s 5.3%. The enhanced revenue growth reflects the success of converting legacy subscribers to a paid subscription. The paid subscription began in the first quarter of 2025, with subscription revenues recognized pro-ratably over the subscription period. As such, we expect that revenue growth will accelerate as it adds subscriptions throughout the year.&nbsp;



Get the Full Report







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Travelzoo  (TZOO) - Off To A Solid Start

Advertising Agencies

Media &amp; Entertainment

Travelzoo

TZOO

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Wednesday, April 30, 2025



ARLP is a diversified natural resource company that generates operating and royalty income from coal produced by its mining complexes and royalty income from mineral interests it owns in strategic oil &amp; gas producing regions in the United States, primarily the Permian, Anadarko and Williston basins. ARLP currently produces coal from seven mining complexes its subsidiaries operate in Illinois, Indiana, Kentucky, Maryland and West Virginia. ARLP also operates a coal loading terminal on the Ohio River at Mount Vernon, Indiana. ARLP markets its coal production to major domestic and international utilities and industrial users and is currently the second largest coal producer in the eastern United States. In addition, ARLP is positioning itself as an energy provider for the future by leveraging its core technology and operating competencies to make strategic investments in the fast growing energy and infrastructure transition.



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



First quarter financial results.&nbsp;Alliance reported first quarter adjusted EBITDA and earnings per unit (EPU) of $159.9 million and $0.57, respectively, compared to $238.4 million and $1.21 during the prior year period. We had projected EBITDA and EPU of $143.8 million and $0.48. While total revenue of $540.5 million was just shy of our $541.1 million estimate, we underestimated coal sales and overstated transportation revenue. Consequently, transportation expense was also overstated. Total operating expenses were $446.2 million compared to our $462.3 million forecast.



Corporate outlook for 2025 and 2026.&nbsp;Management’s guidance for 2025 was little changed, except for increasing the range for total coal sales tonnage, increasing expense as a percentage of oil &amp; gas royalty revenue, depreciation expense, and lowering net interest expense expectations. For 2026, management expects the average coal sales price per ton to trend lower. Due to higher-priced, multi-contracts rolling off, the average sales price per ton could be 4% to 5% below the midpoint of ARLP’s 2025 guidance. We think planned 2025 long wall moves and actions to improve productivity and cost effectiveness could help offset lower prices.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/27437">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Wednesday, April 30, 2025



ARLP is a diversified natural resource company that generates operating and royalty income from coal produced by its mining complexes and royalty income from mineral interests it owns in strategic oil &amp; gas producing regions in the United States, primarily the Permian, Anadarko and Williston basins. ARLP currently produces coal from seven mining complexes its subsidiaries operate in Illinois, Indiana, Kentucky, Maryland and West Virginia. ARLP also operates a coal loading terminal on the Ohio River at Mount Vernon, Indiana. ARLP markets its coal production to major domestic and international utilities and industrial users and is currently the second largest coal producer in the eastern United States. In addition, ARLP is positioning itself as an energy provider for the future by leveraging its core technology and operating competencies to make strategic investments in the fast growing energy and infrastructure transition.



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



First quarter financial results.&nbsp;Alliance reported first quarter adjusted EBITDA and earnings per unit (EPU) of $159.9 million and $0.57, respectively, compared to $238.4 million and $1.21 during the prior year period. We had projected EBITDA and EPU of $143.8 million and $0.48. While total revenue of $540.5 million was just shy of our $541.1 million estimate, we underestimated coal sales and overstated transportation revenue. Consequently, transportation expense was also overstated. Total operating expenses were $446.2 million compared to our $462.3 million forecast.



Corporate outlook for 2025 and 2026.&nbsp;Management’s guidance for 2025 was little changed, except for increasing the range for total coal sales tonnage, increasing expense as a percentage of oil &amp; gas royalty revenue, depreciation expense, and lowering net interest expense expectations. For 2026, management expects the average coal sales price per ton to trend lower. Due to higher-priced, multi-contracts rolling off, the average sales price per ton could be 4% to 5% below the midpoint of ARLP’s 2025 guidance. We think planned 2025 long wall moves and actions to improve productivity and cost effectiveness could help offset lower prices.



Get the Full Report







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Alliance Resource Partners (ARLP) - First Quarter Results Above Our Estimates; Stronger Second Half Expected

Alliance Resource Partners

ARLP

Natural Resouces

Thermal Coal

<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>Key Points - Consumer confidence fell to 86 in April, its lowest since early 2020. - Job openings declined to a four-year low, with inflation expectations hitting 7%. - Short-term economic outlook dropped sharply, signaling rising recession fears.</td></tr></tbody></table></figure>



US consumer confidence took a sharp hit in April, falling for the fifth consecutive month and hitting its lowest level since the height of the COVID-19 pandemic. Amid growing anxieties around job security and inflation, data released Tuesday paints a sobering picture of how consumers view the economy — and their personal financial futures — under the growing shadow of President Trump’s trade escalation.



The Conference Board’s Consumer Confidence Index dropped to 86 in April from a revised 92.9 in March, falling short of economist expectations. Most striking was the steep drop in the Expectations Index, which gauges consumers’ short-term outlook for income, employment, and business conditions. It fell to 54.4 — a level not seen since 2011 and well below the recession-warning threshold of 80.



“Consumers were very much surprised by the severity of those tariffs,” said Yelena Shulyatyeva, senior U.S. economist at the Conference Board. “They actually expect tariffs to affect their finances and their jobs.”



April’s consumer survey, which overlapped with President Trump’s sweeping “Liberation Day” tariff announcement, reflects mounting public concern about how those policies will ripple through household budgets and the broader economy. Inflation expectations surged, with the average 12-month forecast rising to 7%, the highest in over two years.



Labor market sentiment, too, is souring. The share of respondents expecting fewer jobs in the next six months jumped to 32.1%, matching levels not seen since April 2009 during the Great Recession. That pessimism is echoed in the latest Job Openings and Labor Turnover Survey (JOLTS), which revealed that job openings slid to 7.19 million in March — the lowest since late 2020. While hiring held steady at 5.4 million, the ratio of openings to unemployed workers dropped, signaling reduced employer appetite for expansion.



"The hiring rate remains stuck at relatively low levels, which is usually consistent with a higher level of unemployment," said Oxford Economics’ Nancy Vanden Houten, noting that the current pace of layoffs has artificially kept the unemployment rate in check.



Worryingly, consumer outlooks on income have also turned negative for the first time in five years. Fewer people now expect their income to grow, suggesting that inflation and employment concerns are affecting personal financial sentiment, not just macroeconomic views.



Still, perceptions of present-day conditions — such as current job availability and business activity — remain relatively stable. This disconnect between the present and future suggests a market caught between hope and unease, with near-term fears driven by rising costs and a softening labor environment.



Looking ahead, the April jobs report due Friday will offer a more detailed snapshot. Economists expect it to show a slowdown, with 133,000 jobs added and the unemployment rate holding steady at 4.2%. If confirmed, that would mark a meaningful shift from the stronger figures seen earlier this year.



For now, both consumers and economists are bracing for what may come next — from potential rate cuts to new fiscal shocks — in a climate increasingly shaped by political volatility and global economic uncertainty.

Key Points&#8211; Consumer confidence fell to 86 in April, its lowest since early 2020.&#8211; Job openings declined to a four-year low, with inflation expectations hitting 7%.&#8211; Short-term economic outlook dropped sharply, signaling rising recession fears.



US consumer confidence took a sharp hit in April, falling for the fifth consecutive month and hitting its lowest level since the height of the COVID-19 pandemic. Amid growing anxieties around job security and inflation, data released Tuesday paints a sobering picture of how consumers view the economy — and their personal financial futures — under the growing shadow of President Trump’s trade escalation.



The Conference Board’s Consumer Confidence Index dropped to 86 in April from a revised 92.9 in March, falling short of economist expectations. Most striking was the steep drop in the Expectations Index, which gauges consumers’ short-term outlook for income, employment, and business conditions. It fell to 54.4 — a level not seen since 2011 and well below the recession-warning threshold of 80.



“Consumers were very much surprised by the severity of those tariffs,” said Yelena Shulyatyeva, senior U.S. economist at the Conference Board. “They actually expect tariffs to affect their finances and their jobs.”



April’s consumer survey, which overlapped with President Trump’s sweeping “Liberation Day” tariff announcement, reflects mounting public concern about how those policies will ripple through household budgets and the broader economy. Inflation expectations surged, with the average 12-month forecast rising to 7%, the highest in over two years.



Labor market sentiment, too, is souring. The share of respondents expecting fewer jobs in the next six months jumped to 32.1%, matching levels not seen since April 2009 during the Great Recession. That pessimism is echoed in the latest Job Openings and Labor Turnover Survey (JOLTS), which revealed that job openings slid to 7.19 million in March — the lowest since late 2020. While hiring held steady at 5.4 million, the ratio of openings to unemployed workers dropped, signaling reduced employer appetite for expansion.



&#8220;The hiring rate remains stuck at relatively low levels, which is usually consistent with a higher level of unemployment,&#8221; said Oxford Economics’ Nancy Vanden Houten, noting that the current pace of layoffs has artificially kept the unemployment rate in check.



Worryingly, consumer outlooks on income have also turned negative for the first time in five years. Fewer people now expect their income to grow, suggesting that inflation and employment concerns are affecting personal financial sentiment, not just macroeconomic views.



Still, perceptions of present-day conditions — such as current job availability and business activity — remain relatively stable. This disconnect between the present and future suggests a market caught between hope and unease, with near-term fears driven by rising costs and a softening labor environment.



Looking ahead, the April jobs report due Friday will offer a more detailed snapshot. Economists expect it to show a slowdown, with 133,000 jobs added and the unemployment rate holding steady at 4.2%. If confirmed, that would mark a meaningful shift from the stronger figures seen earlier this year.



For now, both consumers and economists are bracing for what may come next — from potential rate cuts to new fiscal shocks — in a climate increasingly shaped by political volatility and global economic uncertainty.

Consumer Confidence Crumbles as Job Market Cools and Inflation Fears Mount

Consumer Confidence

Economy

Jobs Report

Trump Administration

Noble Capital Markets Research Morning Call

<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>Key Points: - Novartis to acquire Regulus for up to $1.7B, including $7/share upfront and $7/share tied to farabursen approval. - Farabursen, a potential first-in-class ADPKD treatment, heads into Phase 3 with FDA alignment. - Boosts Novartis’s kidney disease pipeline and commitment to innovation in rare conditions.</td></tr></tbody></table></figure>



Novartis AG announced plans to acquire Regulus Therapeutics Inc. in a transaction valued at up to $1.7 billion, reinforcing the Swiss pharmaceutical giant's strategy to deepen its portfolio in renal and genetic disease treatments. The deal includes an upfront cash payment of $7.00 per share, representing approximately $800 million in equity value, and an additional $7.00 per share tied to a regulatory milestone via a contingent value right (CVR), pending approval of Regulus's lead drug candidate, farabursen.



Farabursen is being developed as a novel treatment for autosomal dominant polycystic kidney disease (ADPKD), a condition with limited current options and significant unmet clinical need. If approved, farabursen could become the first systemic therapy of its kind in this indication, offering a potentially superior safety and efficacy profile compared to existing treatments.



The acquisition reflects a growing trend in the biopharma sector where large-cap pharmaceutical companies pursue innovative pipelines through targeted M&amp;A. In recent quarters, the industry has seen an uptick in transactions focused on small to mid-sized biotech firms that specialize in high-impact therapies for rare or underserved diseases. Regulus’s focus on microRNA-based therapies, a field once viewed as experimental, is now receiving renewed attention as advances in RNA technology improve target precision and therapeutic delivery.



For Novartis, the move expands its nephrology franchise and bolsters its pipeline in genetic disorders, aligning with the company’s long-term innovation strategy. Financially, the deal signals confidence in both Regulus’s platform and farabursen’s development prospects. The 274% premium to Regulus’s 60-day volume-weighted average price underscores the strategic value Novartis sees in the program.



The transaction is expected to close in the second half of 2025, subject to regulatory approval and the successful tender of a majority of Regulus’s outstanding shares. Once finalized, Regulus will become a wholly owned subsidiary of Novartis, with its operations and development programs integrated into Novartis’s global R&amp;D structure.



The deal may also serve as a bellwether for continued consolidation in biotech, particularly among companies advancing oligonucleotide or RNA-based therapeutics. Investors are likely to see the acquisition as further validation of microRNA platforms, potentially reinvigorating interest in similar early-stage biotech firms.



At a time when cost pressures and generic competition are accelerating across the pharmaceutical landscape, acquiring promising assets with a clear regulatory path remains a preferred strategy for growth. For Regulus, integration with Novartis offers the financial and operational muscle needed to take farabursen through the final stages of development and, if approved, to global markets.



As the biotech sector continues to recalibrate from recent valuation contractions, strategic acquisitions like this illustrate the enduring value of focused innovation, especially in areas with limited treatment alternatives and high unmet demand.

Key Points: &#8211; Novartis to acquire Regulus for up to $1.7B, including $7/share upfront and $7/share tied to farabursen approval.&#8211; Farabursen, a potential first-in-class ADPKD treatment, heads into Phase 3 with FDA alignment.&#8211; Boosts Novartis’s kidney disease pipeline and commitment to innovation in rare conditions.



Novartis AG announced plans to acquire Regulus Therapeutics Inc. in a transaction valued at up to $1.7 billion, reinforcing the Swiss pharmaceutical giant&#8217;s strategy to deepen its portfolio in renal and genetic disease treatments. The deal includes an upfront cash payment of $7.00 per share, representing approximately $800 million in equity value, and an additional $7.00 per share tied to a regulatory milestone via a contingent value right (CVR), pending approval of Regulus&#8217;s lead drug candidate, farabursen.



Farabursen is being developed as a novel treatment for autosomal dominant polycystic kidney disease (ADPKD), a condition with limited current options and significant unmet clinical need. If approved, farabursen could become the first systemic therapy of its kind in this indication, offering a potentially superior safety and efficacy profile compared to existing treatments.



The acquisition reflects a growing trend in the biopharma sector where large-cap pharmaceutical companies pursue innovative pipelines through targeted M&amp;A. In recent quarters, the industry has seen an uptick in transactions focused on small to mid-sized biotech firms that specialize in high-impact therapies for rare or underserved diseases. Regulus’s focus on microRNA-based therapies, a field once viewed as experimental, is now receiving renewed attention as advances in RNA technology improve target precision and therapeutic delivery.



For Novartis, the move expands its nephrology franchise and bolsters its pipeline in genetic disorders, aligning with the company’s long-term innovation strategy. Financially, the deal signals confidence in both Regulus’s platform and farabursen’s development prospects. The 274% premium to Regulus’s 60-day volume-weighted average price underscores the strategic value Novartis sees in the program.



The transaction is expected to close in the second half of 2025, subject to regulatory approval and the successful tender of a majority of Regulus’s outstanding shares. Once finalized, Regulus will become a wholly owned subsidiary of Novartis, with its operations and development programs integrated into Novartis’s global R&amp;D structure.



The deal may also serve as a bellwether for continued consolidation in biotech, particularly among companies advancing oligonucleotide or RNA-based therapeutics. Investors are likely to see the acquisition as further validation of microRNA platforms, potentially reinvigorating interest in similar early-stage biotech firms.



At a time when cost pressures and generic competition are accelerating across the pharmaceutical landscape, acquiring promising assets with a clear regulatory path remains a preferred strategy for growth. For Regulus, integration with Novartis offers the financial and operational muscle needed to take farabursen through the final stages of development and, if approved, to global markets.



As the biotech sector continues to recalibrate from recent valuation contractions, strategic acquisitions like this illustrate the enduring value of focused innovation, especially in areas with limited treatment alternatives and high unmet demand.

Novartis to Acquire Regulus Therapeutics in $1.7 Billion Biotech Buyout

Acquisitions

Biotech

Mergers

Novartis

Regulus Therapeutics

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/07/drct_logo.png" alt="" class="wp-image-47216" style="width:200px"/></figure>



<a href="https://www.channelchek.com/company/drct">Research News and Market Data on Direct Digital</a>



April 29, 2025 8:30 am EDT



HOUSTON,&nbsp;April 29, 2025&nbsp;/PRNewswire/ -- Direct Digital Holdings, Inc. (Nasdaq: DRCT) ("Direct Digital Holdings" or the "Company"), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC ("Colossus SSP") and Orange 142, LLC ("Orange 142"), today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Tuesday, May 6, 2025 after the U.S. stock market closes.



Management will host a conference call and webcast on the same day at 5:00 PM ET to discuss the results. The live webcast and replay can be accessed at&nbsp;<a href="https://ir.directdigitalholdings.com/" target="_blank" rel="noreferrer noopener">https://ir.directdigitalholdings.com/</a>.



About Direct Digital Holdings Direct Digital Holdings (Nasdaq: DRCT) combines cutting-edge sell-side and buy-side advertising solutions, providing data-driven digital media strategies that enhance reach and performance for brands, agencies, and publishers of all sizes. Our sell-side platform, Colossus SSP, offers curated access to premium, growth-oriented media properties throughout the digital ecosystem. On the buy-side, Orange 142 delivers customized, audience-focused digital marketing and advertising solutions that enable mid-market and enterprise companies to achieve measurable results across a range of platforms, including programmatic, search, social, CTV, and influencer marketing. With extensive expertise in high-growth sectors such as Energy, Healthcare, Travel &amp; Tourism, and Financial Services, our teams deliver performance strategies that connect brands with their ideal audiences.



At Direct Digital Holdings, we prioritize personal relationships by humanizing technology, ensuring each client receives dedicated support and tailored digital marketing solutions regardless of company size. This empowers everyone to thrive by generating billions of monthly impressions across display, CTV, in-app, and emerging media channels through advanced targeting, comprehensive data insights, and cross-platform activation. DDH is "Digital advertising built for everyone."



Contacts:



Investors: IMS Investor Relations Walter Frank/Jennifer Belodeau (203) 972-9200 <a href="mailto:investors@directdigitalholdings.com" target="_blank" rel="noreferrer noopener">investors@directdigitalholdings.com</a>

Research News and Market Data on Direct Digital



April 29, 2025 8:30 am EDT



HOUSTON,&nbsp;April 29, 2025&nbsp;/PRNewswire/ &#8212; Direct Digital Holdings, Inc. (Nasdaq: DRCT) (&#8220;Direct Digital Holdings&#8221; or the &#8220;Company&#8221;), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC (&#8220;Colossus SSP&#8221;) and Orange 142, LLC (&#8220;Orange 142&#8221;), today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Tuesday, May 6, 2025 after the U.S. stock market closes.



Management will host a conference call and webcast on the same day at 5:00 PM ET to discuss the results. The live webcast and replay can be accessed at&nbsp;https://ir.directdigitalholdings.com/.



About Direct Digital HoldingsDirect Digital Holdings (Nasdaq: DRCT) combines cutting-edge sell-side and buy-side advertising solutions, providing data-driven digital media strategies that enhance reach and performance for brands, agencies, and publishers of all sizes. Our sell-side platform, Colossus SSP, offers curated access to premium, growth-oriented media properties throughout the digital ecosystem. On the buy-side, Orange 142 delivers customized, audience-focused digital marketing and advertising solutions that enable mid-market and enterprise companies to achieve measurable results across a range of platforms, including programmatic, search, social, CTV, and influencer marketing. With extensive expertise in high-growth sectors such as Energy, Healthcare, Travel &amp; Tourism, and Financial Services, our teams deliver performance strategies that connect brands with their ideal audiences.



At Direct Digital Holdings, we prioritize personal relationships by humanizing technology, ensuring each client receives dedicated support and tailored digital marketing solutions regardless of company size. This empowers everyone to thrive by generating billions of monthly impressions across display, CTV, in-app, and emerging media channels through advanced targeting, comprehensive data insights, and cross-platform activation. DDH is &#8220;Digital advertising built for everyone.&#8221;



Contacts:



Investors:IMS Investor RelationsWalter Frank/Jennifer Belodeau(203) 972-9200investors@directdigitalholdings.com

Release - Direct Digital Holdings to Report First Quarter 2025 Financial Results

Direct Digital Holdings

DRCT

Research News and Market Data on Tonix Pharmaceuticals



April 29, 2025 9:05am EDT



Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells



TNX-1700 is in preclinical development for gastric and colorectal cancers



CHATHAM, N.J., April 29, 2025 (GLOBE NEWSWIRE) &#8212; Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in a poster presentation at the American Association for Cancer Research (AACR) 2025 Annual Meeting, held April 25-30, 2025, in Chicago, IL. A copy of the Company’s presentation is available under the&nbsp;Scientific Presentations&nbsp;tab of the Tonix website at&nbsp;www.tonixpharma.com. The presentation titled, “TFF2-mediated CXCR4 partial agonism outperforms CXCR4 antagonism in reducing murine gastric cancer by suppressing PMN-MDSC generation,” demonstrated positive data in gastric cancer animal models. In the AACR presentation, a fusion protein of murine trefoil factor family member 2- murine serum albumin (mTFF2-MSA) was studied. Tonix is developing human TFF2-human serum albumin (hTFF2-HAS) as TNX-1700.



“The combination therapy of mTFF2-MSA with anti-PD1 treatment shows promise in reducing immunosuppression in the tumor microenvironment (TME) in animal models,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “We are excited to develop TNX-1700 (TFF2-HAS) as the lead program in our immuno-oncology pipeline, by testing potential dosing strategies, and establishing potential clinical biomarkers through preclinical models.”



Immunosuppressive neutrophils, also known as polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), are a major component in solid tumors that significantly hinder anti-tumor activity1,2. Despite being short-lived, their continuous replenishment from the bone marrow sustains their potent immunosuppression in the TME3. Stromal cells in the TME promote immunosuppression by recruiting MDSCs via secretion of CXCL12. Trefoil Factor 2 (TFF2), a secreted peptide of the trefoil factor family, has displayed activity as a partial agonist of CXCR44,5. Data presented in the poster demonstrated that TFF2-MSA selectively reduces immunosuppressive neutrophils and cancer-driven granulopoiesis. Treatment with TFF2-MSA, in combination with an anti-PD1 antibody, induced robust anti-tumoral CD8+ T cell responses, inhibiting tumor invasion. TFF2 reduction correlated with elevated PMN-MDSCs in gastric cancer patients, highlighting the potential negative correlation between TFF2 and PMN-MDSCs levels.



About Trefoil Factor Family Member 2 (TFF2)



Human TFF2 is a secreted protein, encoded by the TFF2 gene in humans, that is expressed in gastrointestinal mucosa where it functions to protect and repair mucosa. TFF2 is also expressed at low levels in splenic immune cells and is now appreciated to have intravascular roles in the spleen and in the tumor microenvironment. In gastric cancer, TFF2 is epigenetically silenced, and TFF2 is suggested to be protective against cancer development through several mechanisms. Tonix is developing TNX-1700 (rTFF2-HSA) for the treatment of gastric and colon cancers under a license from Columbia University. The inventor of the core technology at Columbia is Dr. Timothy Wang, who is an expert in the molecular mechanisms of carcinogenesis whose research has focused on the carcinogenic role of inflammation in modulating stem cell functions. Dr. Wang demonstrated that knocking out the mTFF2 gene in mice leads to faster tumor growth and that overexpression of TFF2 markedly suppresses tumor growth by curtailing the homing, differentiation, and expansion of MDSCs to allow activation of cancer-killing CD8+&nbsp;T cells. He went on to show that a novel engineered form of recombinant murine TFF2 (mTFF2-CTP) had an extended half-life&nbsp;in vivo&nbsp;and was able to suppress MDSCs and tumor growth in an animal model of colorectal cancer. Later, he showed in gastric cancer models that suppressing MDSCs using chemotherapy enhances the effectiveness of anti-PD1 therapy and significantly reduces tumor growth.&nbsp;Dr. Wang proposed the concept of employing rTFF2 in combination with other therapies in cancer prevention and early treatment.



1Kim W, et al. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. Gastroenterology. 2021 Feb;160(3):781-7962Veglia F, et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med. 2021 Apr 5;218(4):e20201803.3Colligan SH, et al. Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression. J Clin Invest. 2022 Dec1;132(23):e158661.4Dubeykovskaya Z, et al. Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines. J Biol Chem. 2009 Feb 6;284(6):3650-62.5Dubeykovskaya Z, et al. Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer. Nat Commun. 2016 Feb 4;7:10517.



Tonix Pharmaceuticals Holding Corp.*



Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace®&nbsp;SymTouch®&nbsp;(sumatriptan injection) 3 mg and Tosymra®&nbsp;(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.



* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.



Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.



This press release and further information about Tonix can be found at&nbsp;www.tonixpharma.com.



Forward Looking Statements



Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix&#8217;s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix&#8217;s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.



Investor Contact



Jessica MorrisTonix Pharmaceuticalsinvestor.relations@tonixpharma.com(862) 799-8599



Peter VozzoICR Healthcarepeter.vozzo@icrhealthcare.com(443) 213-0505



Media Contact



Ray JordanPutnam Insightsray@putnaminsights.com(949) 245-5432



Indication and Usage



Zembrace®&nbsp;SymTouch®&nbsp;(sumatriptan succinate) injection (Zembrace) and Tosymra®&nbsp;(sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.



Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.



Important Safety Information



Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:




discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back



severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw



pain or discomfort in your arms, back, neck, jaw or stomach



shortness of breath with or without chest discomfort



breaking out in a cold sweat



nausea or vomiting



feeling lightheaded




Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.



Do not use Zembrace or Tosymra if you have:




history of heart problems



narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)



uncontrolled high blood pressure



hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.



had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation



severe liver problems



taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.



are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.



an allergy to sumatriptan or any of the components of Zembrace or Tosymra




Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.



Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.



Zembrace and Tosymra may cause serious side effects including:




changes in color or sensation in your fingers and toes



sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever



cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet



increased blood pressure including a sudden severe increase even if you have no history of high blood pressure



medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.



serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.



hives (itchy bumps); swelling of your tongue, mouth, or throat



seizures even in people who have never had seizures before




The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).



Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.



This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.



You are encouraged to report adverse effects of prescription drugs to the FDA. Visit&nbsp;www.fda.gov/medwatch, or call 1-800-FDA-1088.







Source: Tonix Pharmaceuticals Holding Corp.



Released April 29, 2025

Release - Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Biotechnology

Health

TNXP

Tonix Pharmaceuticals

<figure class="wp-block-image aligncenter size-medium"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/03/ocgn_logo-300x300.png" alt="" class="wp-image-7513"/></figure>



<a href="https://www.channelchek.com/company/ocgn">Research News and Market Data on Ocugen</a>



April 29, 2025



MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah from May 4-8, 2025, and Retina World Congress at the Marriott Harbor Beach Resort in Ft. Lauderdale, Florida from May 8-11, 2025.



“We look forward to sharing more about the potential of our modifier gene therapy platform and the meaningful results we are seeing in the clinic during these two important meetings for the retina community,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “Ocugen remains on track to deliver on our commitment to file three Biologics License Applications&nbsp;(BLAs)/Marketing Authorization Applications (MAAs) in the next three years—potentially addressing significant unmet medical need for large patient populations through our gene-agnostic approach.”



The ARVO Annual Meeting is a premiere gathering for eye and vision scientists from across the globe, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions. Retina World Congress brings together leading retina specialists from every continent to achieve a global scientific and clinical exchange in retinal health.



Ocugen’s presence in Utah kicks off with the Company Showcase at Eyecelerator, presented by Dr. Huma Qamar, Chief Medical Officer at Ocugen, and continues through presentations and thought leadership engagement at ARVO.



Eyecelerator @ Park City 2025



Session: Retina—Gene Therapy and Novel Mechanisms of Action Showcase Location: Grand Hyatt Deer Valley,&nbsp;Strawberry Ballroom, Park City, UT Date: Friday, May 2, 2025 Time: 2:06 p.m. MDT Presenter: Dr. Huma Qamar



ARVO



Exhibitor Education Forum Two-Year Follow-Up of a Phase 1/2 Clinical Trial for the Safety and Efficacy of OCU400 Novel Modifier Gene Therapy for Retinitis Pigmentosa Location: Exhibitor Floor, Section 1037 Date: Monday, May 5, 2025 Time: 2 p.m. MDT&nbsp; Presenter: Benjamin Bakall, MD, Ph.D., Assistant Clinical Professor, University of Arizona, College of Medicine–Phoenix, and Director for Clinical Research, Director for The Inherited Retinal Disease and Visual Function Clinic, Associated Retina Consultants



An Evaluation of the Safety and Efficacy of Novel Modifier Gene Therapy OCU410 for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Location: Exhibitor Floor, Section 1037 Date: Tuesday, May 6, 2025 Time: 2 p.m. MDT Presenter: Syed M. Shah, MD, FACS, Vice Chair for Research and Digital Medicine, Director of Retina Service at Gundersen Health System, La Crosse, Wisconsin



Safety and Efficacy of OCU410ST: A Phase 1/2 Trial of a Novel Modifier Gene Therapy for Stargardt Disease (GARDian) Location: Exhibitor Floor, Section 1037 Date: Wednesday, May 7, 2025 Time: 2 p.m. MDT Presenter: Neena Haider, Ph.D., Faculty Harvard Medical School and Founder, CEO, Shifa Precision



Paper Session Preliminary Safety and Efficacy of OCU410 for Treatment of Geographic Atrophy: Phase 1/2 OCU410: The Age-related Macular Degeneration (ArMaDa) Study Update Presentation Number: 3675&nbsp; Session Number and Title: 358/AMD Clinical research II&nbsp; Location: Ballroom J&nbsp; Date:&nbsp;Tuesday, May 6, 2025 Time: 4:15 p.m. MDT Presenter: Syed M. Shah, MD, FACS, Vice Chair for Research and Digital Medicine, Director of Retina Service at Gundersen Health System, La Crosse, Wisconsin



Poster Session A0513: Safety and Efficacy of OCU410ST for the Treatment of Stargardt Disease: Phase 1/2 Study Update Location: Hall A-E Date: Thursday, May 8, 2025 Time: 2 p.m. MDT Presenter: Ramiro Maldonado, MD, Duke Center for Ophthalmic Genetics, Duke Pediatric Retina, Adult vitreo-Retinal diseases



Dr. Qamar will represent Ocugen at Retina World Congress to share the Company presentation and serve alongside notable retinal surgeons and industry peers during a panel discussion.



Retina World Congress



Retina Unplugged Inherited and Rare Retinal Diseases Session Moderators: Rishi P. Singh, MD, FASRS and Kourous A. Rezaei, MD Location: Grand Ballroom Date: Thursday, May 8, 2025 Time: 10:35 am – 11:12 a.m. EDT



Ocugen is committed to bringing game-changing therapies to treat inherited retinal diseases as well as blindness diseases affecting millions to market and working even harder to provide access to patients globally.



About Ocugen, Inc. Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=sEdVy4QB2G-OyxMPvgKxxbYqvcbLiLgyuYBPWE1HgQw4HucZ8SxKdXqyN-RHX5gyb801XWwCZMGV7ZTAN-BcKHBOYU8I9GE2H7KvhySWEdZAE7r2Gu_bzOaOmfFuFzTG7s8gCty06s6qtY0OmyHgOXEL4EuuwBjN3GPqIkYeCq-Orq55_JZ8GATt9HrvOYfB1J0fTPmA3tkoFWnjia6WEhLxMPgaQ1aCPOBm2cPwuGZ_ncUF_RHRwkJ9mC8Y6IePGbnpRbg_EWtpl-ohvkxfIhYmNTHhOX2JFbWt891fM-EG_ObM4TrujMrisfwUcg_WWV7jhvwL1Yg0gn3eKggz0hY5pIKlLhPYs3gmpdpnsTY-zjU0d9YbLHR3FmuqIf1RDC30aUCfi7kSsJBtq7BHZZORVsMtnWJb4CCsxAAFzLwk1RWv3d6Jblg_uHODBO-a" rel="noreferrer noopener" target="_blank">www.ocugen.com</a>&nbsp;and follow us on&nbsp;<a href="https://www.globenewswire.com/Tracker?data=ToGUmXFSfGIhGlell23T8mJVWfOB46aynqn27IsuIbX31UU2_A-FqTCa-XtfLGJOzboIk13_OYMp_wd0PkeWCs4N7UJT0DcnGocUbvx_3awQ2bHUSax-Z_Tt98RFct5xGe9exSFVsYht58AfcEHONNX3-0M7Nk3dUK_5L2ty3SEBwuWxIOS2oJv1bTYJX0WLuGKk1YxGJvLOsQ-DNPnsb3zxMeJyYn6MMw3RyVTmvKbzJvqYKQDn-zS_4aO2SwxGMlI-hFYfpJduMwJMAE5mIUzK6ktZlR1En_x-Lr9Ha4u4WKKS4ASQFvGUbfxO00DBa8OVeWLb1PFB5bmukoaPJWLQGEZcuC7MnG2waRUfvJ68WBJVnJrw0Ok5EXNaSyif1GrYV155jJ4hH4Ng0fZ7sqClEuH4O3qpleGWf7aPlg9pQbfu62yAYhHnC4S22SS7XsYuaWdzN6jvLyIlH79Dj93RPrX-ydnTkU4z256Is13uHIdYJKwssR-oGMD9twRQ" rel="noreferrer noopener" target="_blank">X</a>&nbsp;and&nbsp;<a href="https://www.globenewswire.com/Tracker?data=ta8mRedz9_G2tzcrjY62h_pRXhOuoulgSe1LsNjPUIQDU5ePznXHEhVFEbfFy4ouodQ6-bdxS3so0_ux1Cxw5Tm_MR-3ITL9-d7KuDNoF33UeWLXMzuAVtMBnehHifUKbC7SkJhmHY4Pqm4FmDCEcIAi7AOr458djGhe7lMkIeR3fABbTp8064iLQ-DO_5116J3lcNQ-9cTJpMjCif6SdA0b2bwT_hXQ3j_YxamDB2uoX4dKrHXU0TQSik7nnADZTBm8LjmX3OO90Rc1uA2q24SWJ1g_KIhLoE7XPh5VH0niRlnzUQsunfVzAG2LXhFXCg5qMlWmkdyG0G6dTEfxPmBKA8SVvyq37EemMc4qPmmrg77w5nu8v_p6B_3IMK4-rHAjknUSB0GFTEevQUxaSYAuIcRRpaIKXmS7Jpk3256PgzNn0YphIskyxgiJDZB_" rel="noreferrer noopener" target="_blank">LinkedIn.</a>



Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.



Contact: Tiffany Hamilton AVP, Head of Communications <a href="https://www.globenewswire.com/Tracker?data=QdEqfQbK4dph6s6vAIoJSWLz4OO7sa1JaIHs1R2XNiD3sH-rKo5LmYBbyYUHdNBfK-vA4nwG_1x2nW8wz85o50475wHjpU4D6owEFmWt97l7_eQ0PpPSv48EnW5iYjnW" rel="noreferrer noopener" target="_blank">Tiffany.Hamilton@ocugen.com</a>

Research News and Market Data on Ocugen



April 29, 2025



MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah from May 4-8, 2025, and Retina World Congress at the Marriott Harbor Beach Resort in Ft. Lauderdale, Florida from May 8-11, 2025.



“We look forward to sharing more about the potential of our modifier gene therapy platform and the meaningful results we are seeing in the clinic during these two important meetings for the retina community,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “Ocugen remains on track to deliver on our commitment to file three Biologics License Applications&nbsp;(BLAs)/Marketing Authorization Applications (MAAs) in the next three years—potentially addressing significant unmet medical need for large patient populations through our gene-agnostic approach.”



The ARVO Annual Meeting is a premiere gathering for eye and vision scientists from across the globe, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions. Retina World Congress brings together leading retina specialists from every continent to achieve a global scientific and clinical exchange in retinal health.



Ocugen’s presence in Utah kicks off with the Company Showcase at Eyecelerator, presented by Dr. Huma Qamar, Chief Medical Officer at Ocugen, and continues through presentations and thought leadership engagement at ARVO.



Eyecelerator @ Park City 2025



Session: Retina—Gene Therapy and Novel Mechanisms of Action ShowcaseLocation: Grand Hyatt Deer Valley,&nbsp;Strawberry Ballroom, Park City, UTDate: Friday, May 2, 2025Time: 2:06 p.m. MDTPresenter: Dr. Huma Qamar



ARVO



Exhibitor Education ForumTwo-Year Follow-Up of a Phase 1/2 Clinical Trial for the Safety and Efficacy of OCU400 Novel Modifier Gene Therapy for Retinitis PigmentosaLocation: Exhibitor Floor, Section 1037Date: Monday, May 5, 2025Time: 2 p.m. MDT&nbsp;Presenter: Benjamin Bakall, MD, Ph.D., Assistant Clinical Professor, University of Arizona, College of Medicine–Phoenix, and Director for Clinical Research, Director for The Inherited Retinal Disease and Visual Function Clinic, Associated Retina Consultants



An Evaluation of the Safety and Efficacy of Novel Modifier Gene Therapy OCU410 for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationLocation: Exhibitor Floor, Section 1037Date: Tuesday, May 6, 2025Time: 2 p.m. MDTPresenter: Syed M. Shah, MD, FACS, Vice Chair for Research and Digital Medicine, Director of Retina Service at Gundersen Health System, La Crosse, Wisconsin



Safety and Efficacy of OCU410ST: A Phase 1/2 Trial of a Novel Modifier Gene Therapy for Stargardt Disease (GARDian)Location: Exhibitor Floor, Section 1037Date: Wednesday, May 7, 2025Time: 2 p.m. MDTPresenter: Neena Haider, Ph.D., Faculty Harvard Medical School and Founder, CEO, Shifa Precision



Paper SessionPreliminary Safety and Efficacy of OCU410 for Treatment of Geographic Atrophy: Phase 1/2 OCU410: The Age-related Macular Degeneration (ArMaDa) Study UpdatePresentation Number: 3675&nbsp;Session Number and Title: 358/AMD Clinical research II&nbsp;Location: Ballroom J&nbsp;Date:&nbsp;Tuesday, May 6, 2025Time: 4:15 p.m. MDTPresenter: Syed M. Shah, MD, FACS, Vice Chair for Research and Digital Medicine, Director of Retina Service at Gundersen Health System, La Crosse, Wisconsin



Poster SessionA0513: Safety and Efficacy of OCU410ST for the Treatment of Stargardt Disease: Phase 1/2 Study UpdateLocation: Hall A-EDate: Thursday, May 8, 2025Time: 2 p.m. MDTPresenter: Ramiro Maldonado, MD, Duke Center for Ophthalmic Genetics, Duke Pediatric Retina, Adult vitreo-Retinal diseases



Dr. Qamar will represent Ocugen at Retina World Congress to share the Company presentation and serve alongside notable retinal surgeons and industry peers during a panel discussion.



Retina World Congress



Retina UnpluggedInherited and Rare Retinal Diseases SessionModerators: Rishi P. Singh, MD, FASRS and Kourous A. Rezaei, MDLocation: Grand BallroomDate: Thursday, May 8, 2025Time: 10:35 am – 11:12 a.m. EDT



Ocugen is committed to bringing game-changing therapies to treat inherited retinal diseases as well as blindness diseases affecting millions to market and working even harder to provide access to patients globally.



About Ocugen, Inc.Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at&nbsp;www.ocugen.com&nbsp;and follow us on&nbsp;X&nbsp;and&nbsp;LinkedIn.



Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.



Contact:Tiffany HamiltonAVP, Head of CommunicationsTiffany.Hamilton@ocugen.com

Release - Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

OCGN

Ocugen

Vision

<figure class="wp-block-image aligncenter size-medium"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/lode-logo-pr-300x64.png" alt="" class="wp-image-49690"/></figure>



<a href="https://www.channelchek.com/company/lode">Research News and Market Data on Comstock</a>



April 29, 2025



Virginia City, Nevada,&nbsp;April 29, 2025&nbsp;– Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) is pleased to announce that the Company’s Executive Chairman &amp; CEO, Corrado De Gasperis, and COO, William McCarthy will be providing an overview of recent financial results and current business updates on Thursday, May 8, 2025, at 4:30pm ET. We invite all investors and other interested parties to register for the webinar at the link below.



Date: Thursday, May 8, 2025 Time: 4:30pm ET Register:&nbsp;<a href="https://lp.comstockinc.com/webinar-5.8?__hstc=176612858.162b1c3ecaf932ec006e08ee6704ad81.1745954361053.1745954361053.1745954361053.1&amp;__hssc=176612858.2.1745954361053&amp;__hsfp=1966047304" target="_blank" rel="noreferrer noopener">Webinar Registration</a>



There will be an allotted time following the live presentation for a Q&amp;A session. Unaddressed questions will be reviewed by management and responded to accordingly. You may submit your question(s) beforehand in the registration form (linked above) or by email at:&nbsp;<a href="mailto:ir@comstockinc.com">ir@comstockinc.com</a>.



About Comstock Inc.



Comstock Inc. (NYSE: LODE) innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock’s innovations group is also developing and using artificial intelligence technologies for advanced materials development and mineral discovery for sustainable mining. To learn more, please visit&nbsp;<a href="http://www.comstock.inc/">www.comstock.inc</a>.



Comstock Social Media Policy



Comstock Inc. has used, and intends to continue using, its&nbsp;<a href="https://comstock.inc/investors/">investor relations</a>&nbsp;link and main website at&nbsp;<a href="http://www.comstock.inc/">www.comstock.inc</a>&nbsp;in addition to its&nbsp;<a href="https://x.com/comstockinc" target="_blank" rel="noreferrer noopener">X.com</a>,&nbsp;<a href="https://www.linkedin.com/company/comstock/" target="_blank" rel="noreferrer noopener">LinkedIn</a>&nbsp;and&nbsp;<a href="https://www.youtube.com/@comstockinc" target="_blank" rel="noreferrer noopener">YouTube</a>&nbsp;accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.



Contacts



For investor inquiries: William McCarthy, Chief Operating Officer Tel (775) 413-6222 <a href="mailto:ir@comstockinc.com">ir@comstockinc.com</a>



For media inquiries: Tracy Saville, Director of Marketing Tel (775) 847-7573 <a href="mailto:media@comstockinc.com">media@comstockinc.com</a>



Forward-Looking Statements&nbsp;



This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

Research News and Market Data on Comstock



April 29, 2025



Virginia City, Nevada,&nbsp;April 29, 2025&nbsp;– Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) is pleased to announce that the Company’s Executive Chairman &amp; CEO, Corrado De Gasperis, and COO, William McCarthy will be providing an overview of recent financial results and current business updates on Thursday, May 8, 2025, at 4:30pm ET. We invite all investors and other interested parties to register for the webinar at the link below.



Date: Thursday, May 8, 2025Time: 4:30pm ETRegister:&nbsp;Webinar Registration



There will be an allotted time following the live presentation for a Q&amp;A session. Unaddressed questions will be reviewed by management and responded to accordingly. You may submit your question(s) beforehand in the registration form (linked above) or by email at:&nbsp;ir@comstockinc.com.



About Comstock Inc.



Comstock Inc. (NYSE: LODE) innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock’s innovations group is also developing and using artificial intelligence technologies for advanced materials development and mineral discovery for sustainable mining. To learn more, please visit&nbsp;www.comstock.inc.



Comstock Social Media Policy



Comstock Inc. has used, and intends to continue using, its&nbsp;investor relations&nbsp;link and main website at&nbsp;www.comstock.inc&nbsp;in addition to its&nbsp;X.com,&nbsp;LinkedIn&nbsp;and&nbsp;YouTube&nbsp;accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.



Contacts



For investor inquiries:William McCarthy, Chief Operating OfficerTel (775) 413-6222ir@comstockinc.com



For media inquiries:Tracy Saville, Director of MarketingTel (775) 847-7573media@comstockinc.com



Forward-Looking Statements&nbsp;



This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

Release - Comstock to Host First Quarter 2025 Earnings and Business Update Call

Comstock

LODE

Natural Resources

Footer menu

Contact Me

Feedback

Test form

Event Registration

The NobleCon20 VIP Giveaway

Main menu

The NobleCon20 VIP Giveaway – Terms and Conditions
1. Organizer The NobleCon20 VIP Giveaway (“Contest”) is organized by Noble Financial Group and Channelchek (“Organizers”).
2. Eligibility The Contest is open to legal residents of the United States who are 18 years of age or older at the time of entry. Employees of the Organizers, their affiliates, subsidiaries, advertising and promotion agencies, and immediate family members are not eligible to participate.
3. Contest Period The Contest begins on [Start Date] and ends on October 31, 2024, at 11:59 PM ET. Entries submitted after the Contest Period will not be considered.
4. How to Enter To enter the Contest:
<ul>
<li>You must be a registered and verified Channelchek member.</li>
<li>You must complete the Contest entry form available at [Entry Form URL].</li>
</ul>
5. Prize The prize package includes:
<ul>
<li>Round-trip economy airfare for two (2) to South Florida to attend NobleCon20.</li>
<li>Two (2) hotel rooms for the duration of NobleCon20.</li>
<li>Two (2) tickets to NobleCon20, including access to all official NobleCon20 events.</li>
<li>Two (2) VIP meet-and-greet upgrades to the headline event featuring three (3) of the Sharks from ABC’s Shark Tank.</li>
</ul>
There will be one (1) winner chosen. All travel and accommodations are subject to availability and must be arranged through the Organizers. No substitution, transfer, or cash equivalent of prizes is permitted.
6. Winner Selection The winner will be selected on November 1, 2024. The winner will be notified via email using the contact information provided during entry. If the winner does not respond within seven (7) days of the notification, the Organizers reserve the right to select an alternate winner.
7. General Conditions
<ul>
<li>No purchase is necessary to enter or win.</li>
<li>The Contest is void where prohibited by law.</li>
<li>The prize does not include a presentation slot at NobleCon20.</li>
<li>By participating, entrants agree to be bound by these Terms and Conditions and the decisions of the Organizers, which are final and binding in all respects.</li>
<li>The Organizers reserve the right to disqualify any entry that is incomplete, misdirected, or in violation of these Terms and Conditions.</li>
</ul>
8. Privacy By entering the Contest, you agree that your personal information may be used by the Organizers in accordance with their privacy policies.
9. Limitation of Liability The Organizers are not responsible for any incorrect or inaccurate information, technical failures, or unauthorized intervention in the Contest. The Organizers are not liable for any injury or damage to persons or property resulting from participation in the Contest or acceptance or use of any prize.
10. Contact Information For questions or further information about the Contest, please contact the Organizers at contact@channelchek.com.

NobleCon20 VIP Contest Terms

NobleCon20 VIP Giveaway

Show form on click button

<h3 style="text-align: center;">Enjoying Channelchek?</h3>
There&#8217;s more to explore!
<a href="https://www.channelchek.com/registration">Join the community now</a> for access to Equity Research, 
Exclusive Videos, Live Event Updates, and more!
It&#8217;s absolutely free to join.
<a href="https://www.channelchek.com/registration"><img loading="lazy" decoding="async" class=" wp-image-64177 aligncenter" src="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg" alt="" width="351" height="301" srcset="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg 300w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-1024x876.jpg 1024w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-768x657.jpg 768w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-1536x1314.jpg 1536w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-2048x1752.jpg 2048w" sizes="auto, (max-width: 351px) 100vw, 351px" /></a>
<script id="xverse-wallet-provider" src="chrome-extension://idnnbdplmphpflfnlkomgpfbpcgelopg/inpage.js"></script>